STAT

SEPTEMBER 21, 2023

When Sarah, a mother of two, was diagnosed with breast cancer in 2021 at the age of 43, she carefully considered where to go for care. She had been referred by her doctor to Beth Israel Deaconess Medical Center, where she received a mammogram and the cancer diagnosis. Continue to STAT+ to read the full story…

Chemotherapy 342

Chemotherapy Hospitals 342

STAT

APRIL 25, 2024

In 2021 alone, the use of generic and biosimilar drugs saved $373 billion in health expenditures. Important categories of drugs — from antibiotics to chemotherapies to saline solution — experience persistent shortages and inadequate quality. Today, however, generic drugs seem to be a victim of their success.

Prescription Filling 247

Prescription Filling Biosimilars Chemotherapy 247

STAT

NOVEMBER 12, 2024

billion when it went public in 2021, is now just $111 million.  The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily. Over the course of this year, its stock has plummeted 72% and its market capitalization, which was $3.5

Chemotherapy 232

Chemotherapy 232

Express Pharma

SEPTEMBER 19, 2023

Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030. With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles.

Chemotherapy 105

Chemotherapy Compounding 105

pharmaphorum

SEPTEMBER 16, 2024

Incyte had previously tried to get a green light for the drug as a second-line, post-chemotherapy treatment for SCAC, but that application was rejected in 2021.

Chemotherapy 88

Chemotherapy 88

Express Pharma

JUNE 1, 2023

Venus Remedies secured a marketing authorisation from the largest market in the Gulf Cooperation Council (GCC) region for Docetaxel, a chemotherapy drug. billion pharma market (as in 2021) signifies a major step in the global expansion strategy of Venus Remedies in the oncology space.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

MARCH 14, 2023

Platinum-based cancer drug compositions is a key innovation area in chemotherapy Platinum-based drugs are chemotherapeutic agents used for the treatment of cancer. Several platinum-based drugs such as cisplatin, carboplatin and oxaliplatin are widely used in cancer therapy.

Chemotherapy 52

Chemotherapy Mayo Clinic Compounding Pharmaceutical Companies 52

European Pharmaceutical Review

DECEMBER 6, 2022

In July 2021, the French temporary authorisation for use (Autorisation Temporaire d’Utilisation, ATU) programme was the subject of a major reform, initially published within the 2021 healthcare plan on the 14th December 2020 (Article 78 – La Loi de financement de la sécurité sociale , FSSL). 03/11/2021. ✓. 27/10/2021.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

MARCH 14, 2023

Purine derivatives-based cancer drug compositions is a key innovation area in chemotherapy Purine is an important heterocyclic nucleus in the chemical architecture of many bioactive compounds. Among its key functions, it interacts with nucleic acids and enzymes during their synthesis and function.

Chemotherapy 52

Chemotherapy Compounding Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

AUGUST 12, 2022

The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52 percent). Analysis data cut-off: 27 August 2021. Key secondary endpoints include progression-free survival (PFS), duration of response (DoR) and safety. Median PFS iv , months (95% CI). DCR v , percent (95% CI).

Chemotherapy 98

Chemotherapy 98

Big Molecule Watch

MAY 22, 2023

According to the press release, FYLNETRA—Amneal’s third biosimilar launch in the United States since late last year—is used to treat neutropenia (low neutrophils, a type of white blood cell that fights infection) which is commonly experienced by patients undergoing chemotherapy.

Biosimilars 72

Biosimilars Chemotherapy 72

pharmaphorum

JANUARY 26, 2022

At the moment the only other BiTE to reach the US market is Amgen’s CD19-targeting Blincyto (blinatumomab), which has been approved for various types of leukaemia and made $340 million in sales in the first nine months of 2021.

Chemotherapy 124

Chemotherapy Labelling Immunity Immunization 124

Express Pharma

FEBRUARY 19, 2024

billion in 2021 to $21.8 GlobalData’s latest report, “Colorectal Cancer: Eight-Market Drug Forecast and Market Analysis,” reveals that the number of globally diagnosed incident cases is expected to increase from 1 million in 2021 to 1.32 With a projected market expansion from $15.8 billion in 2031, at a CAGR of 3.3 million in 2031.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

JUNE 6, 2022

Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021. Another research note from SVB Securities predicted that repotrectinib could eventually become a $1.5

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

FEBRUARY 21, 2022

In the study, Enhertu was given to patients with HER2-low, unresectable and/or metastatic breast cancer previously treated with one to two prior lines of chemotherapy. AZ and Daiichi said the new data will be shared with global health authorities with a view to expanding its use even further.

Chemotherapy 132

Chemotherapy Labelling 132

European Pharmaceutical Review

JULY 12, 2022

AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). . The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunity 98

Immunity Immunization Chemotherapy 98

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Tivdak, a tissue-factor targeting ADC that was developed in collaboration with Genmab, was approved in 2021.

Chemotherapy 59

Chemotherapy Compounding 59

Express Pharma

APRIL 25, 2023

Venus Remedies has secured marketing authorisation from the UK for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma. million in 2021 and is expected to grow to $661.16 The global market size of Cisplatin was valued at $394.5

Chemotherapy 73

Chemotherapy 73

pharmaphorum

MAY 29, 2022

The pair of new approvals are based on the results of the CheckMate-648 trial, and are for Opdivo (nivolumab) paired with chemotherapy or BMS’ CTLA4 inhibitor Yervoy (ipilimumab) as first-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCC) that can’t be treated with surgery.

Chemotherapy 59

Chemotherapy 59

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda. billion in 2028.

Chemotherapy 52

Chemotherapy Packaging Documentation 52

European Pharmaceutical Review

AUGUST 10, 2022

” T-Dxd was approved by the European Medicines Agency (EMA) in 2021 for the treatment of unresectable or metastatic HER2-positive breast cancer. It is a chemical conjugate of an antibody against HER2 (trastuzumab) and a chemotherapy drug (deruxtecan).

Chemotherapy 98

Chemotherapy Labelling Hospitals 98

pharmaphorum

NOVEMBER 26, 2020

Y-mAbs said last month it is expecting to resubmit omburtamab for approval to the FDA in late 2020 or early 2021, and will also start clinical trials of a next-generation version of the drug before year-end in neuroblastoma as well as B7-H3-positive leptomeningeal tumours. And combination trials with chemotherapy are also planned.

Chemotherapy 105

Chemotherapy Labelling 105

Express Pharma

MARCH 24, 2023

The issuance of a patent in the US in 2021 and now in Japan for SBP-101 are significant milestones.” In data evaluated from clinical studies to date, ivospemin has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which can be chemotherapy-related adverse events.

Chemotherapy 94

Chemotherapy Compounding Diabetes 94

pharmaphorum

FEBRUARY 8, 2021

— Bristol Myers Squibb (@bmsnews) February 5, 2021. At the moment there are limited fallback options for patients whose lymphoma progresses despite first line chemotherapy and anti-CD20 treatment. Our first #CARTcelltherapy is now approved by the #FDA.

Chemotherapy 111

Chemotherapy Labelling 111

European Pharmaceutical Review

DECEMBER 12, 2022

Without the experimental CD7 CAR-T cell therapy, having previously undergone unsuccessful conventional treatments including chemotherapy and a bone marrow transplant, the patient’s only other option was palliative care. Six months later, the patient is doing well and is recovering at home.

Chemotherapy 124

Chemotherapy Hospitals 124

pharmaphorum

APRIL 7, 2022

Previously, urothelial carcinoma patients were eligible only to receive supportive care until their cancer progressed, after which they could get second-line treatment with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), chemotherapy with docetaxel or paclitaxel, or continued supportive care.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

AUGUST 31, 2022

The 345-subject CodeBreaK 200 trial of once-daily Lumakras (sotorasib) met its primary objective of improving progression-free survival (PFS) compared to chemotherapy with intravenous docetaxel in KRAS G12C-mutated NSCLC patients previously treated with platinum-based doublet chemotherapy and checkpoint inhibitor therapy.

Chemotherapy 64

Chemotherapy Labelling 64

European Pharmaceutical Review

OCTOBER 19, 2023

How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.

Chemotherapy 105

Chemotherapy Compounding Immunity Immunization 105

Pharmaceutical Technology

MAY 12, 2023

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. The company generated almost $2bn in revenue in 2022, a close to 25% increase from 2021.

Chemotherapy 64

Chemotherapy Compounding 64

pharmaphorum

FEBRUARY 7, 2022

The drug was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for this type of cancer in June 2021 based on results from the GARNET trial , which included women who progressed on or after platinum-based chemotherapy.

Chemotherapy 52

Chemotherapy Labelling 52

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. These patients face a poorer prognosis and shorter survival rates compared with lung cancer driven by more common EGFR mutations. 2012; 23(8): 6 – 9. Personalized medicine at FDA.

Immunity 98

Immunity Immunization Chemotherapy 98

pharmaphorum

JANUARY 25, 2023

9,273,135 and 9,320,811, which cover the use of a CTLA4 inhibitor in combination with a PD-1 inhibitor and chemotherapy drug gemcitabine, respectively. In 2021, BMS sold over $2bn worth of Yervoy, according to a report by the company.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

JULY 19, 2022

China’s Simcere Pharmaceutical has been granted approval in its home market for Cosela, a drug designed to limit the side effects of cancer chemotherapy, partnered with US biotech G1 Therapeutics. Simcere said that the number of new cancer patients requiring chemotherapy in China is expected to reach 4.2

Chemotherapy 59

Chemotherapy 59

pharmaphorum

JANUARY 10, 2022

The EU approval is based on the phase 2 CodeBreak 100 study in 733 subjects, which found that treatment with Lumykras was associated with a 37% objective response rate (ORR), defined as a 30% or greater reduction in tumour volume, when used as a second-line therapy for KRAS G12C-mutated NSCLC after chemotherapy and/or immunotherapy.

Chemotherapy 59

Chemotherapy Labelling 59

pharmaphorum

JANUARY 26, 2023

BTC study positive In the BTC trial – codenamed KEYNOTE-966 – a combination of Keytruda with chemotherapy showed a “statistically significant and clinically meaningful” improvement in overall survival versus chemo alone in newly diagnosed patients, and will form the basis of regulatory filings.

Chemotherapy 59

Chemotherapy Immunity Immunization 59

pharmaphorum

OCTOBER 3, 2022

It is therefore an interesting development that sugemalimab was given an Innovation Passport in NICE’s Innovative Licensing and Access Pathway (ILAP) in October 2021. Single Technology Appraisal: Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer ID4001. National Institute for Clinical Excellence.

Chemotherapy 98

Chemotherapy Biosimilars Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

MAY 26, 2022

The US regulator has approved Tibsovo (ivosidenib) in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) as a first-line therapy for IDH1-mutated acute myeloid leukaemia (AML), expanding the eligible patient population for the drug.

Chemotherapy 52

Chemotherapy Labelling 52